Talnif Cápsulas Blandas

Array
(
    [ID] => 20056
    [post_author] => 16
    [post_date] => 2025-07-24 08:28:05
    [post_date_gmt] => 2025-07-24 11:28:05
    [post_content] => 
Forma farmacéutica:
Cápsulas Blandas
Composición:
Cada cápsula blanda contiene: Tafamidis 61 mg.
Acción Terapéutica:
Estabilizador selectivo de la transtiretina.
Indicaciones:
Talnif está indicado para el tratamiento de la cardiomiopatía por amiloidosis producida por depósito de transtiretina (ATTR-CM), de tipo natural o hereditaria, en pacientes adultos, para reducir la mortalidad y las internaciones por causas cardiovasculares.
Presentaciones:
Envases conteniendo 30 cápsulas blandas.
    [post_title] => Talnif Cápsulas Blandas
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => talnif
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2025-07-24 12:13:34
    [post_modified_gmt] => 2025-07-24 15:13:34
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://www.bago.com.ar/vademecum/?post_type=productos&p=20056
    [menu_order] => 0
    [post_type] => productos
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
    [prospecto_para_pacientes] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 20059
                    [post_author] => 16
                    [post_date] => 2025-07-24 08:52:36
                    [post_date_gmt] => 2025-07-24 11:52:36
                    [post_content] => 
                    [post_title] => TALNIF CpB Información paciente Disp. 6231-24
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => talnif-cpb-informacion-paciente-disp-6231-24
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-24 08:52:36
                    [post_modified_gmt] => 2025-07-24 11:52:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://www.bago.com.ar/vademecum/wp-content/uploads/2025/07/TALNIF-CpB-Informacion-paciente-Disp.-6231-24.pdf
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => application/pdf
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [url_para_mayor_informacion_video] => 
    [url_para_mayor_informacion] => 
    [url_productos_consumo_masivo] => 
    [prospecto] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 20060
                    [post_author] => 16
                    [post_date] => 2025-07-24 08:53:39
                    [post_date_gmt] => 2025-07-24 11:53:39
                    [post_content] => 
                    [post_title] => TALNIF CpB Prospecto Disp. 6231-24_compressed
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => talnif-cpb-prospecto-disp-6231-24_compressed
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-24 08:53:39
                    [post_modified_gmt] => 2025-07-24 11:53:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://www.bago.com.ar/vademecum/wp-content/uploads/2025/07/TALNIF-CpB-Prospecto-Disp.-6231-24_compressed.pdf
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => application/pdf
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [presentacion_img] => Array
        (
        )

    [logo_img] => Array
        (
        )

    [foto_producto] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 20063
                    [post_author] => 16
                    [post_date] => 2025-07-24 12:12:58
                    [post_date_gmt] => 2025-07-24 15:12:58
                    [post_content] => 
                    [post_title] => talnif-img
                    [post_excerpt] => 
                    [post_status] => inherit
                    [comment_status] => open
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => talnif-img-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-07-24 12:12:58
                    [post_modified_gmt] => 2025-07-24 15:12:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://www.bago.com.ar/vademecum/wp-content/uploads/2025/07/talnif-img-1.png
                    [menu_order] => 0
                    [post_type] => attachment
                    [post_mime_type] => image/png
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [fotos_lanzamiento] => Array
        (
        )

    [especialidad] => Array
        (
        )

    [marca] => Array
        (
            [0] => Talnif
        )

    [principio_activo] => Array
        (
            [0] => Tafamidis
        )

    [post_content_formatted] => 
Forma farmacéutica:
Cápsulas Blandas
Composición:
Cada cápsula blanda contiene: Tafamidis 61 mg.
Acción Terapéutica:
Estabilizador selectivo de la transtiretina.
Indicaciones:
Talnif está indicado para el tratamiento de la cardiomiopatía por amiloidosis producida por depósito de transtiretina (ATTR-CM), de tipo natural o hereditaria, en pacientes adultos, para reducir la mortalidad y las internaciones por causas cardiovasculares.
Presentaciones:
Envases conteniendo 30 cápsulas blandas.

)

Array
(
    [_wp_attached_file] => Array
        (
            [0] => prospectos/TALNIF-CpB-Prospecto-Disp.-6231-24_compressed.pdf
        )

    [_wp_attachment_metadata] => Array
        (
            [0] => a:1:{s:8:"filesize";i:2586169;}
        )

)

Array
(
    [_wp_attached_file] => Array
        (
            [0] => 2025/07/TALNIF-CpB-Informacion-paciente-Disp.-6231-24.pdf
        )

    [_wp_attachment_metadata] => Array
        (
            [0] => a:1:{s:8:"filesize";i:1009855;}
        )

)

anexo_congre_single